Combatting COVID-19 – Existing Antivirals to the Rescue
Why re-invent the wheel? Innovators around the world have already discovered and designed many compounds. Some may be very effective against SARS-CoV-2. If we could develop treatments based on these drugs, we might save valuable development time, especially if they are safe and well-tolerated.
Pharmaceutical companies, biotechs and academia have teamed up globally to bring together a library of all these antivirals and have started screening them.
Join Johan Neyts from KU Leuven and Marnix Van Loock from Janssen Pharmaceutica NV for a discussion on key learnings in the global partnership of therapeutics screening.
The information on this webpage, including in the videos, is proprietary or licensed to Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (“JJI”) and is for informational purposes only. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson or its affiliates. The information presented in the videos is specific and applicable to region in which the original presentation took place. Many videos contain information from, or sessions given by, third parties. Please note that only those third parties that provide this information are responsible for it. By providing this information, JJI does not endorse these third parties or any of the information provided in these videos, and JJI makes no representations, warranties, or assurances, express or implied, as to the content or the information presented and is not responsible for any use of this information by you.